Clinical research site network CenExel Clinical Research announced on Tuesday the appointment of Dr. Sy Pretorius as chief executive officer, effective 1 May 2026.
Dr. Pretorius succeeds Ryan Brooks, who will remain a member of the company's board of directors.
CenExel said that Dr. Pretorius joins the company with more than three decades of experience in clinical research leadership, spanning senior executive and management roles where he was instrumental in driving global clinical development programmes, early-phase research, and integrated clinical trial services.
Dr. Pretorius currently serves as CEO of Ergomed Group, where he leads value creation efforts across the PrimeVigilance, Ergomed CRO and ADAMAS businesses after the group transitioned from the public market to private equity ownership. Prior to joining Ergomed, he served as chief operating officer at EVERSANA, where he led drug and device commercialisation services. Earlier, as president of Clinical Development and chief medical officer at PAREXEL, he oversaw a USD3.6bn global P&L and led more than 16,000 employees worldwide.
Racura Oncology identifies mechanism of action for (E,E)-bisantrene
Bayer to acquire Perfuse Therapeutics in USD2.45bn deal to expand ophthalmology pipeline
NextCell Pharma and FUJIFILM Biosciences launch global MSC research product
ZYUS Life Sciences receives second US pain management patent
MingMed Biotechnology presents QA102 Phase II trial data in intermediate AMD at ARVO 2026
Vanda Pharmaceuticals NEREUS (tradipitant) commercially available for Motion sickness in US
Specialised Therapeutics' chronic graft-versus-host disease therapy approved in Australia
Telix Pharmaceuticals' MAA for TLX101-Px (Pixlumi) accepted for European review
Bambusa Therapeutics completes patient enrolment in Phase 1b/2a trial for atopic dermatitis
Lab Thread launches unified digital platform for biological research workflows
Curocell secures full approval for RIMQARTO to enter CAR-T therapy market